口服帕比司他联合阿扎胞苷治疗成人MDS、CMML或原始细胞≤30%的AML的1b/2b期多中心研究
这项1b/2b期多中心试验(n=113)在较高危MDS、慢性粒单核细胞白血病或原始细胞<30%的少原始细胞急性髓系白血病患者中,确定帕比司他联合阿扎胞苷的最大耐受剂量未达到,推荐2期剂量为帕比司他30 mg联合阿扎胞苷75 mg/m2;联合组复合完全缓解率高于阿扎胞苷单药组,但1年总生存率和至进展时间无显著差异,联合组3/4级不良事件和治疗中死亡更多。
要点
- 推荐2期剂量为帕比司他30 mg联合阿扎胞苷75 mg/m2,最大耐受剂量未达到。
- 联合组复合完全缓解率27.5%(95%CI 14.6-43.9%) vs 阿扎胞苷组14.3%(5.4-28.5%)。
- 1年总生存率联合组60%(50-80%) vs 阿扎胞苷组70%(50-80%),无显著差异。
核心结论
- 帕比司他联合阿扎胞苷的推荐2期剂量为帕比司他30 mg联合阿扎胞苷75 mg/m2,最大耐受剂量未达到。
- 联合组复合完全缓解率高于阿扎胞苷单药组,但1年总生存率和至进展时间无显著差异,且联合组3/4级不良事件和治疗中死亡更多。
- 进一步优化剂量或给药方案可能改善该方案的风险/获益特征。
研究设计与样本
- 1b/2b期多中心试验(n=113),纳入较高危MDS、慢性粒单核细胞白血病或原始细胞<30%的少原始细胞急性髓系白血病成人患者。
- 1b期确定帕比司他联合阿扎胞苷的最大耐受剂量或推荐2期剂量,2b期评估联合方案对比阿扎胞苷单药的早期疗效和安全性。
主要发现
- 最大耐受剂量未达到,推荐2期剂量为帕比司他30 mg联合阿扎胞苷75 mg/m2。
- 联合组复合完全缓解率27.5%(95%CI 14.6-43.9%),阿扎胞苷单药组14.3%(5.4-28.5%)。
- 1年总生存率联合组60%(50-80%) vs 阿扎胞苷单药组70%(50-80%),无显著差异。
- 至进展时间联合组70%(40-90%) vs 阿扎胞苷单药组70%(40-80%),无显著差异。
- 3/4级不良事件联合组97.4% vs 阿扎胞苷单药组81.0%,治疗中死亡联合组13.2% vs 阿扎胞苷单药组4.8%。
关键数值与推荐
- 推荐2期剂量为帕比司他30 mg联合阿扎胞苷75 mg/m2。
- 复合完全缓解包括完全缓解、形态学完全缓解伴血细胞计数不完全恢复和骨髓完全缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 进一步优化剂量或给药方案可能改善该方案的风险/获益特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is <2 years, novel agents are needed to improve outcomes. This phase 1b/2b trial (n=113) was designed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of panobinostat (PAN)+AZA (phase 1b) and evaluate the early efficacy and safety of PAN+AZA vs AZA monotherapy (phase 2b) in patients with higher-risk MDS, chronic myelomonocytic leukemia or oligoblastic acute myeloid leukemia with <30% blasts. The MTD was not reached; the RP2D was PAN 30 mg plus AZA 75 mg/m2. More patients receiving PAN+AZA achieved a composite complete response ([CR)+morphologic CR with incomplete blood count+bone marrow CR (27.5% (95% CI, 14.6-43.9%)) vs AZA (14.3% (5.4-28.5%)). However, no significant difference was observed in the 1-year OS rate (PAN+AZA, 60% (50-80%); AZA, 70% (50-80%)) or time to progression (PAN+AZA, 70% (40-90%); AZA, 70% (40-80%)). More grade 3/4 adverse events (97.4 vs 81.0%) and on-treatment deaths (13.2 vs 4.8%) occurred with PAN+AZA. Further dose or schedule optimization may improve the risk/benefit profile of this regimen.
引用
- Garcia-Manero G, Sekeres MA, Egyed M, et al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts. Leukemia. 2017. PMID: 28546581. doi:10.1038/leu.2017.159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。